Pfizer

Pfizer to offer nearly two dozen low-cost products to poor nations

The products, which are widely available in the US and the European Union, include 23 medicines and vaccines that treat infectious diseases, some cancers and rare and inflammatory conditions

Pfizer to offer all its drugs not-for-profit to 45 lower-income countries

Pfizer has announced it is to supply all its current and future patent-protected medicines and vaccines on a not-for-profit basis to 45 lower-income countries and is talking to other big drugmakers

WEF 2022: Pfizer commits medicines, vaccines to 45 lower-income countries

World Economic Forum (WEF) 2022: The initiative by Pfizer was launched at the World Economic Forum Annual Meeting in Davos 2022

Pfizer's three-dose coronavirus vaccine 80% effective in young kids

Pfizer said that preliminary clinical data showed their three-dose Covid-19 vaccine regimen was 80 per cent effective for children aged between 6 months to 5-years-old

Pfizer/BioNTech say three Covid shots generate good response in under-5s

Three doses of Pfizer's COVID-19 vaccine offer strong protection for children younger than 5, the company announced Monday.

US FDA authorises Pfizer booster shots for children aged 5-11 yrs

The US FDA has granted emergency use authorisation for a booster dose of the Pfizer-BioNTech vaccine for children aged between 5-11 years at least 5 months after completion of primary vaccine series

Cipla will use Covid-19 bulk drugs inventory when demand rises

The Covid-19 portfolio contributed 5-6 per cent of Cipla's turnover during peak Covid waves, the firm said

Pfizer to pay $11.6 bn for Biohaven Pharmaceutical to tap migraine market

Pfizer will pay $148.50 a share for all of New Haven, Connecticut-based Biohaven's outstanding stock, according to a statement Tuesday

Pfizer sets up drug development centre at Chennai's IIT Research Park

The centre integrates two essential functions under the export-oriented undertaking of Pfizer: Pharmaceutical Sciences (PharmSci) and Global Technology and Engineering (GT&E) Centre of Excellence.

Pfizer's profit grows by 61% in first qtr; company revises 2022 forecast

Sales of Pfizer's COVID-19 vaccine and treatment pushed the drugmaker well past expectations in the first quarter, as profit grew 61per cent.

Pfizer stock falls as Covid pill fails in preventive therapy trial

The trial failure, along with reports of rebounding coronavirus levels in some patients who have completed a course of Paxlovid, are unlikely to change the drug's sales potential

'Hire me': Star Trek star, others ping Elon Musk for jobs at Twitter

'Hire me to run Twitter as VP of Product,' tweeted Nikita Bier, co-founder of a positivity-focused polling app called tbh that was acquired by Meta Platforms

Pfizer's anti-Covid pill Paxlovid could be available in India next week

This assumes significance as Covid cases are on the rise in the country, especially in the National Capital Region (NCR)

Pfizer to seek Covid-19 booster shots for healthy 5- to 11-year-olds in US

Now Pfizer says new data shows healthy 5- to 11-year-olds could benefit from another kid-sized shot

Indian Covid vaccines better than Pfizer, Moderna says Adar Poonawalla

Covid vaccines

'4th vaccine dose protects elderly from Covid but protection wanes quickly'

A 4th dose of Pfizer vaccine lowered rates of Covid-19 among people aged 60 years or older but protection against the infection appeared short-lived, according to a study conducted in Israel

US pulls GSK's Covid drug as omicron sibling dominates cases

GlaxoSmithKline's IV drug for Covid-19 should no longer be used because it is likely ineffective against the omicron subvariant that now accounts for most US cases, federal health regulators said

FDA authorises second booster of Pfizer/BioNTech, Moderna Covid shots

FDA authorises another booster dose of the Pfizer or Moderna Covid vaccine for people age 50 and up

Strides Pharma Science signs pact with MPP to market Covid-19 drug

Branded as Kovidax, Strides' generic version of the Pfizer oral treatment will be launched in 95 markets as part of the sub-licensing agreement with Medicines Patent Pool (MPP), the drug firm said

Select pharma shares gain on tie-up for Pfizer Covid-19 oral treatment drug

Among individual stocks, Aurobindo Pharma was the top gainer, which rallied 8 per cent to Rs 688.90 on the BSE in intra-day trade.